inTRANSITION FAQs
Frequently Asked Questions
Tell us what you're looking for to find questions and answers about your topic.
Recent FAQs
inTRANSITION FAQs for Service Members and Veterans
Mental Health by the Numbers FAQs
Airborne Hazards and Open Burn Pit Registry: Eligibility and Enrollment
Airborne Hazards and Open Burn Pit Registry: General Information
Individual Longitudinal Exposure Record
MHS Modified Payment and Waiver Program: Overseas Information
MHS Modified Payment and Waiver Program: Implementation Timeline
MHS Modified Payment and Waiver Program: Billing Delays
MHS Modified Payment and Waiver Program: Eligibility Requirements
Popular FAQs
Joint Longitudinal Viewer
The Brandon Act
Individual Longitudinal Exposure Record
Airborne Hazards and Open Burn Pit Registry: Eligibility and Enrollment
TRICARE Formulary
Project 112 SHAD
Prescription Drug Monitoring Program FAQs
Joint Health Information Exchange
VA/DOD Clinical Practice Guideline for Tinnitus
Frequently Asked Questions for Identifiers
We found 869 items
UF BAP Meeting Information June 22 through June 24
Provides the schedule and dial-in instructions for the June BAP meeting
UF BAP Agenda June 22 2026
Provides a list of topics to be covered on June 23rd 2026
UF BAP Agenda Day 1 June 22 2026
Provides a list of topics to be covered the first day of the meeting.
UF BAP agenda Day 3 2026
Provides a list of topics to be covered on Day 3 of June BAP meeting
Background Information May 2025 PT Committee recommendations
Provides clinical and cost-effectiveness conclusions for P&T committee decisions based on evaluation and review of utilization trends.
Background Information Feb 2025 PT committee recommendations
Provides clinical and cost-effectiveness conclusions for formulary placement of agents based on evaluation by P&T committee and utilization review
Background Information May 2025 Addendum July 10 2025 PT committee recommendations
Provides additional clarification and guidance on P&T decisions from May 2025 committee meeting
Background Information August 2025 PT Committee Recommendations
Provides clinical and cost-effectiveness conclusions for P&T committee decisions in August 2025 based on evaluation and review of utilization trends.
Background Information Feb 2026 PT committee recommendations
Provides clinical and cost-effectiveness conclusions for P&T committee decisions based on evaluation and review of utilization trends from the February 2026 meeting
P&T Minutes - May 2026
Provides recommendations of the P&T Committee on formulary inclusion of new drugs, drug class reviews, conclusions from utilization management, and final votes
P&T Minutes - February 2026
Contains summary of proceedings and recommendations for formulary inclusion and drug class reviews evaluated by P&T Committee in February 2026
P&T Minutes - January 16, 2026 - Interim Meeting IL-23 Inhibitors
Contains clarification and instructions for therapeutic substitution of selected medications and explains P&T authorities for therapeutic substitution
P&T Meetings 2025
Cumulative P&T minutes for February, May, August and November 2025 P&T meetings reflecting formulary recommendations and final decisions
P&T Minutes - November 2025
Contains the summary of proceedings, recommendations and actions from November P&T Committee Meeting
P&T Minutes - August 2025
Summarizes the proceedings and recommendations of the P&T committee concerning formulary inclusions and drug class reviews evaluated by P&T committee in November 2025
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil View the external links disclaimer.